Personalized Cancer Treatment Improves Outcomes in New Clinical Trial

New research shows just how powerful personalized cancer treatment can be. A landmark clinical trial led by researchers at the University of California San Diego found that tailoring treatment to the unique DNA of each patient’s tumor significantly improved outcomes – without increasing severe side effects. The findings were published in the Journal of Clinical Oncology.

How the trial worked

Rather than a one-size-fits-all approach, the study used detailed molecular profiling of each patient’s tumor to guide individualized drug combinations. This approach, often called precision oncology, matches treatments to the specific genetic changes driving a person’s cancer.

What it could mean for appendix cancer patients

This trial was not specific to appendix cancer, but it adds to growing evidence that understanding the biology of each tumor can lead to better, more patient-centered care. Appendix cancer is a rare disease with its own genetic features, and research has already shown that some appendix cancers respond to treatments targeted at specific mutations.

Tumor genomic sequencing can identify these mutations. Patients may wish to ask their care team whether sequencing is appropriate for them and how the results might inform treatment options or clinical trial eligibility.

Learn more

Read more about the study.

This summary is for general information only and is not medical advice. Please talk with your care team about what this research may mean for you.